Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Ventana to create a companion diagnostic for Loxo's larotrectinib

Executive Summary

Roche's Ventana Medical Systems Inc. agreed to develop and commercialize a pan-tropomyosin receptor kinase (TRK) immunohistochemistry (IHC) companion diagnostic for Loxo Oncology Inc.'s larotrectinib (LOXO101).
Deal Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
  • Medical Devices
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register